Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Cubist, MorphoSys, AstraZeneca, MedImmune and Takeda. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer’s disease, schizophrenia, diabetes, ADHD and chronic migraine.

Latest News

Jul 7, 2014
Heptares Announces Publication In Nature Of First Structure Of Metabotropic Glutamate Receptor 5 Transmembrane Domain
Jun 30, 2014

Heptares Chief Scientific Officer And Co-founder Fiona Marshall to Present At Royal Society Of Medicine Medical Innovations Summit


Sep 7-11, 2014
Lisbon, Portugal
Presenting: Jon Mason

Sep 15-17, 2014
RSC GPCR MedChem Conference
Basel, Switzerland
Presenting: Giles Brown

© 2012-2014 Heptares Therapeutics